Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients

Abstract

Objective Chaperonin‐containing tailless complex polypeptide 1 subunit 6A (CCT6A) is reported to be an efficient prognostic biomarker in various cancers, but it is rarely reported in astrocytoma. Thus, this study aimed to evaluate the expression of CCT6A and its correlation with disease features and prognosis in astrocytoma patients. Methods Totally, 198 astrocytoma patients who received surgery treatment were enrolled. CCT6A protein expression was determined in the tumor tissues fixed in formalin and embedded in paraffin (FFEP) by immunohistochemistry (IHC) assay. In addition, 133 out of 198 astrocytoma patients had fresh tumor tissues frozen in the liquid nitrogen for the determination of CCT6A mRNA expression by reverse transcription‐quantitative polymerase chain reaction. Results Sixty‐nine (34.8%), 70 (35.4%), 46 (23.2%), and 13 (6.6%) astrocytoma patients had the CCT6A immunohistochemistry (IHC) score of 0–3, 4–6, 7–9, and 10–12, respectively. CCT6A protein expression was correlated with increased World Health Organization (WHO) grade (P < 0.001) and less isocitrate dehydrogenase (IDH) mutation (P = 0.002); meanwhile, CCT6A mRNA expression was only related to elevated WHO grade (P = 0.001). However, CCT6A protein and mRNA expression were not correlated with other clinical features and subsequent treatment modalities (all P > 0.05). Moreover, CCT6A protein high and CCT6A mRNA high were related to shorter accumulating overall survival (OS; both P < 0.05). CCT6A protein high was an independent factor for predicting the worse OS (hazard ratio: 1.821, P = 0.012). Conclusion Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with elevated WHO grade and less IDH mutation; besides, CCT6A high expression is independently associated with unfavorable accumulating OS of astrocytoma patients.

Glioblastoma biomarkers in urinary extracellular vesicles reveal the potential for a ‘liquid gold’ biopsy

“…Similarly, TRiC subunits CCT2, CCT3, CCT4, CCT5, CCT7 and TCP1, were measured in higher levels in the plasma of GBM patients relative to healthy controls, with significant increases in CCT2 and CCT7 [ 5 ]. Another study later corroborated that high CCT6A levels in glioma correlate with elevated WHO grade, fewer IDH1/2 mutations and shorter overall survival [ 44 ].…”

The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges

“…In TBSRTC DC4 nodules, CCT6A-AAbs were capable of detecting borderline and malignant tumors with DSp and DSn values of 100% and 40%, respectively [ 125 ]. Interestingly, more recent studies extensively implicated TCP-1ζ/CCT6A as an oncogenic protein and biomarker of poor prognosis in various human malignancies [ 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 ], rendering its cancer-associated immunogenicity highly biologically relevant.…”